Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers
ABSTRACT Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relaps...
Saved in:
| Published in | Addiction biology Vol. 18; no. 5; pp. 872 - 881 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.09.2013
John Wiley & Sons, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1355-6215 1369-1600 1369-1600 |
| DOI | 10.1111/j.1369-1600.2011.00427.x |
Cover
| Abstract | ABSTRACT
Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within‐subjects, double‐blind, randomized protocol. Over seven sessions, the time‐dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or ‘high’ relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose‐dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose‐related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose‐related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. |
|---|---|
| AbstractList | Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Delta 9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation=0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8mg), dronabinol (10, 20mg) and placebo were assessed. Nabilone (4, 6, 8mg) and dronabinol (10, 20mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2mg) and dronabinol (10mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence.Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 (CB1) agonist oral Δ 9 tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal, but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers, and compare these with dronabinol's effects. Participants ( 4F; 10M ) smoking marijuana 6.6 (SD = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over 7 sessions, the time-dependent subjective, cognitive, and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect, and/or `high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements, and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol and effects were more dose-related, suggesting improved bioavailability. Nabilone was well-tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. ABSTRACT Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within‐subjects, double‐blind, randomized protocol. Over seven sessions, the time‐dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or ‘high’ relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose‐dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose‐related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose‐related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral [Delta]9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence. [PUBLICATION ABSTRACT] |
| Author | Bedi, Gillinder Cooper, Ziva D. Haney, Margaret |
| Author_xml | – sequence: 1 givenname: Gillinder surname: Bedi fullname: Bedi, Gillinder organization: Division on Substance Abuse, New York State Psychiatric Institute, and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA – sequence: 2 givenname: Ziva D. surname: Cooper fullname: Cooper, Ziva D. organization: Division on Substance Abuse, New York State Psychiatric Institute, and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA – sequence: 3 givenname: Margaret surname: Haney fullname: Haney, Margaret email: mh235@columbia.edu organization: Division on Substance Abuse, New York State Psychiatric Institute, and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22260337$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkltv1DAQhS1URC_wF5AlXnggwfbEl0gIqS1QkFZF3MSj5SROcZq1t_Zm2f57nG5ZAU_4xWPNd0ZHnnOMDnzwFiFMSUnzeTmUFERdUEFIyQilJSEVk-X2ATraNw7mmvNCMMoP0XFKAyGUSQ6P0CFjTBAAeYTGL1Mz2HbtNvYFbsOVd3OJje9wa2LnwsakdhpNxF1ItrB9n2G8iqF3o8Whx940bszu7iRdDPPbhxE7j5cmumEy3uC0DNc2psfoYW_GZJ_c3yfo27u3X8_fF4uPFx_OTxeFq6iSBe1rTglIykyrDJUVGAKqNhVrCFNWSl4bpipCFFjomp40VFraMllx3reqhRP0ejd3NTVL27XWr6MZ9Sq6bOlWB-P03x3vfuirsNEAwGsu8oDn9wNiuJlsWuulS60dR-NtmJKmVc0ErYGp_0CZkJwQUWX02T_oEKbo809kSgCRAIpn6umf5veuf-8sA692wM-8gtt9nxI9Z0MPeo6AniOg52zou2zorT59c5aLLC92cpfWdruXm3ithQTJ9ffLCy0_qUV1eQb6M_wCszG9SA |
| ContentType | Journal Article |
| Copyright | 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction. 2013 Society for the Study of Addiction |
| Copyright_xml | – notice: 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction – notice: 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction. – notice: 2013 Society for the Study of Addiction |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM 7QG 7T5 7TM H94 7X8 7TK 5PM |
| DOI | 10.1111/j.1369-1600.2011.00427.x |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Animal Behavior Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic Neurosciences Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Animal Behavior Abstracts Nucleic Acids Abstracts MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Social Welfare & Social Work |
| EISSN | 1369-1600 |
| EndPage | 881 |
| ExternalDocumentID | PMC3335956 3143341251 22260337 ADB427 ark_67375_WNG_7Q8L4NB3_R |
| Genre | article Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDA NIH HHS grantid: DA09236 – fundername: NIDA NIH HHS grantid: K01 DA027755 – fundername: NIDA NIH HHS grantid: K23 DA034877 – fundername: NIDA NIH HHS grantid: P50 DA009236 – fundername: National Institute on Drug Abuse : NIDA grantid: P50 DA009236-19 || DA |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 52M 52O 52T 52U 52V 52W 53G 5GY 5HH 5RE 5VS 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 88E 8FE 8FH 8FI 8FJ 930 A01 A03 AAESR AAEVG AAFWJ AAMMB AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABDBF ABIVO ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCMX ACCZN ACGEJ ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADXPE ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AFBPY AFGKR AFKRA AFPKN AFWVQ AGQPQ AGXDD AHEFC AIACR AIDQK AIDYY AIURR AJWEG ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZQEC AZVAB BAFTC BBNVY BDRZF BENPR BFHJK BHBCM BHPHI BMXJE BPHCQ BROTX BRXPI BSCLL BVXVI C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DRFUL DRMAN DRSTM DUUFO DWQXO EAD EAP EAS EBD EBS EJD EMB EMK EMOBN EPT ESX F00 F01 F04 F21 F5P FEDTE FUBAC FYUFA FZ0 G-S G.N GNUQQ GODZA GROUPED_DOAJ H.X HCIFZ HF~ HMCUK HVGLF HZ~ KBYEO LATKE LEEKS LH4 LITHE LK8 LOXES LP6 LP7 LUTES LW6 LYRES M1P M2M M7P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PSYQQ PUEGO Q.N QB0 Q~Q R.K RIWAO RJQFR ROL RPM RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 UKHRP W8V W99 WBKPD WIH WIJ WIK WNSPC WOHZO WXSBR WYISQ ZZTAW ~IA ~WT 3V. AAHHS ACCFJ ADZOD AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE ALIPV WUP CGR CUY CVF ECM EIF NPM 7QG 7T5 7TM H94 7X8 7TK 5PM |
| ID | FETCH-LOGICAL-i4187-1f95103712ac8a1743a0389a42b028e7759a2840083e3dbf0b17e1c27455fc8c3 |
| ISSN | 1355-6215 1369-1600 |
| IngestDate | Thu Aug 21 14:05:15 EDT 2025 Thu Sep 04 16:41:57 EDT 2025 Fri Sep 05 06:48:48 EDT 2025 Fri Jul 25 12:24:59 EDT 2025 Mon Jul 21 06:06:20 EDT 2025 Wed Jan 22 16:44:34 EST 2025 Tue Sep 09 05:32:37 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Agonist treatment dose-effect profile marijuana dependence dronabinol nabilone |
| Language | English |
| License | 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-i4187-1f95103712ac8a1743a0389a42b028e7759a2840083e3dbf0b17e1c27455fc8c3 |
| Notes | istex:051CF0C528577A1298B935D705102D7A0D74CD8E ark:/67375/WNG-7Q8L4NB3-R ArticleID:ADB427 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 22260337 |
| PQID | 1463073385 |
| PQPubID | 2028711 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3335956 proquest_miscellaneous_1492619328 proquest_miscellaneous_1426750064 proquest_journals_1463073385 pubmed_primary_22260337 wiley_primary_10_1111_j_1369_1600_2011_00427_x_ADB427 istex_primary_ark_67375_WNG_7Q8L4NB3_R |
| PublicationCentury | 2000 |
| PublicationDate | September 2013 |
| PublicationDateYYYYMMDD | 2013-09-01 |
| PublicationDate_xml | – month: 09 year: 2013 text: September 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: United States – name: Leeds |
| PublicationTitle | Addiction biology |
| PublicationTitleAlternate | Addict Biol |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd John Wiley & Sons, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley & Sons, Inc |
| References | Mendelson J, Mello N (1984) Reinforcing effects of oral delta-9 tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 83:351-356. Haney M, Hart C, Vosburg S, Nasser J, Bennett A, Zubaran C, Foltin R (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158-170. Hart C, van Gorp W, Haney M, Foltin R, Fischman M (2001) Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25:757-765. MTP Research Group (2004) Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 72:455-466. Haney M (2007) Opioid antagonism of cannabinoid effects: differences between marijuana smokers and non-marijuana smokers. Neuropsychopharmacology 32:1391-1403. Sheskin DJ (2000) Handbook of Parametric and Nonparametric Statistical Procedures, 2nd edn. Boca Raton, FL: CRC Press LLC. Haney M, Ward A, Comer S, Foltin R, Fischman M (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385-394. McGilveray I (2005) Pharmacokinetics of cannabinoids. Pain Res Manag 10 (Suppl. A): 15A-22A. Threlkeld M, Parran T, Adelman C, Grey S, Yu J (2006) Tramadol versus buprenorpine for the management of acute heroin withdrawal: a retrospective matched cohort control study. Am J Addict 15:186-191. Brook JS, Zhang C, Brook DW (2011) Developmental trajectories of marijuana use from adolescence to adulthood. Arch Pediatr Adolesc Med 165:55-60. Fraser A, Meatherall R (1989) Lack of interference by Nabilone in the EMIT® d.a.u cannabinoid assay, Abbott TDx® cannabinoid assay, and a sensitive TLC assay for delta-9-THC-carboxylic acid. J Anal Toxicol 13:240. Keppel G (1991) Design and Analysis: A Researcher's Handbook, 4th edn. Upper Saddle River, NJ: Prentice Hall. Hart C, Ilan A, Gevins A, Gunderson E, Role K, Colley J, Foltin R (2010) Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacol Biochem Behav 96:333-341. Lemberger L, Rowe H (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18:720-726. Stapleton J, Sutherland G (2011) Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. Addiction 106:824-832. Zobel I, Kech S, van Calker D, Dykierek P, Berger M, Schneibel R, Schramm E (2011) Long-term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patients. Acta Psychiatr Scand 123:276-282. Parrott AC, Garnham NJ, Wesnes K, Pincock C (1996) Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Hum Psychopharmacol 11:391-400. Lemberger L, Rubin A, Wolen R, DeSante K, Rowe H, Forney R, Pence P (1982) Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 9:17-23. Levin F, Mariani J, Brooks D, Pavlicova M, Cheng W, Nunes E (2011) Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116:142-150. Bedi G, Foltin R, Gunderson E, Rabkin J, Hart C, Comer S, Vosburg S, Haney M (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 212:675-686. Chen K, Kandel DB, Davies M (1997) Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend 46:53-67. Budney AJ, Vandrey RG, Hughes J, Moore BA, Bahrenburg B (2007b) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86:22-29. United Nations Office on Drugs and Crime (2007) 2007 World Drug Report. Vienna, Austria: UNODC. Haney M (2002) Effects of smoked marijuana in healthy and HIV + marijuana smokers. J Clin Psychopharmacol 42:34S-40S. Lile J, Kelly T, Hays L (2011) Separate and combined effects of the cannabinoid agonists nabilone and delta9-THC in humans discriminating delta9-THC. Drug Alcohol Depend 116:86-92. Vandrey RG, Budney AJ, Hughes JR, Liguori A (2008) A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 92:48-54. Ben Amar M (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105:1-25. Budney AJ, Moore BA, Rocha HL, Higgins ST (2006) Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 74:307-316. SAMSHA (2010) Results from the 2009 National Survey on Drug Use and Health. Rockville, MD: SAMSHA, Office of Applied Statistics. Folstein MF, Luria R (1973) Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3:479-486. Haney M, Rabkin J, Gunderson E, Foltin R (2005) Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 181:170-178. Grassi MC, Enea D, Ferketich AK, Lu B, Pasquariello S, Nencini P (2011) Effectiveness of varenicline for smoking cessation: a 1-year follow-up study. J Subst Abuse Treat 41:64-70. APA (1994) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association. Lile J, Kelly T, Hays L (2010) Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta-9-Tetrahydrocannabinol. Clin Neuropharmacol 33:235-242. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD (2006) Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse 32:503-517. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM (2007) Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 32:1220-1236. Haney M (2008) Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14:9-21. Ware M, St Arnaud-Trempe E (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:494-503. Wesnes K, Annas P, Edgar C, Deeprose C, Karlsten R, Philipp A, Kalliomaki J, Segerdahl M (2010) Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol 24:1659-1669. Haney M, Hart C, Vosburg S, Comer S, Reed S, Foltin R (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197:157-168. Haney M, Ward A, Comer S, Foltin R, Fischman M (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404. Budney A, Roffman R, Stephens R, Walker D (2007a) Marijuana dependence and its treatment. Addict Sci Clin Pract 4:4-16. Hart C, Haney M, Vosburg S, Comer S, Foltin R (2005) Reinforcing effects of oral Delta-9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 181:237-243. 2011; 116 1984; 83 2010; 33 2006; 74 2004; 29 2006; 32 2010 2010; 105 1997; 46 1975; 18 2006; 15 2008; 14 2007a; 4 2007 1994 1999b; 141 1999a; 141 1991 2007; 32 2008; 92 2001; 25 2007b; 86 1996; 11 2005; 181 2004; 72 2011; 106 2010; 24 2002; 42 2000 2010; 212 1982; 9 2011; 41 2005; 10 2006; 105 1989; 13 2008; 197 2010; 96 2011; 123 2011; 165 1973; 3 |
| References_xml | – reference: Brook JS, Zhang C, Brook DW (2011) Developmental trajectories of marijuana use from adolescence to adulthood. Arch Pediatr Adolesc Med 165:55-60. – reference: Chen K, Kandel DB, Davies M (1997) Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend 46:53-67. – reference: MTP Research Group (2004) Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 72:455-466. – reference: Haney M (2007) Opioid antagonism of cannabinoid effects: differences between marijuana smokers and non-marijuana smokers. Neuropsychopharmacology 32:1391-1403. – reference: Haney M (2002) Effects of smoked marijuana in healthy and HIV + marijuana smokers. J Clin Psychopharmacol 42:34S-40S. – reference: Stapleton J, Sutherland G (2011) Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. Addiction 106:824-832. – reference: SAMSHA (2010) Results from the 2009 National Survey on Drug Use and Health. Rockville, MD: SAMSHA, Office of Applied Statistics. – reference: Keppel G (1991) Design and Analysis: A Researcher's Handbook, 4th edn. Upper Saddle River, NJ: Prentice Hall. – reference: Sheskin DJ (2000) Handbook of Parametric and Nonparametric Statistical Procedures, 2nd edn. Boca Raton, FL: CRC Press LLC. – reference: Budney AJ, Vandrey RG, Hughes J, Moore BA, Bahrenburg B (2007b) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86:22-29. – reference: Ware M, St Arnaud-Trempe E (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:494-503. – reference: Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD (2006) Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse 32:503-517. – reference: Bedi G, Foltin R, Gunderson E, Rabkin J, Hart C, Comer S, Vosburg S, Haney M (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 212:675-686. – reference: Hart C, Ilan A, Gevins A, Gunderson E, Role K, Colley J, Foltin R (2010) Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacol Biochem Behav 96:333-341. – reference: Hart C, Haney M, Vosburg S, Comer S, Foltin R (2005) Reinforcing effects of oral Delta-9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 181:237-243. – reference: Mendelson J, Mello N (1984) Reinforcing effects of oral delta-9 tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 83:351-356. – reference: Haney M, Ward A, Comer S, Foltin R, Fischman M (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404. – reference: Lemberger L, Rubin A, Wolen R, DeSante K, Rowe H, Forney R, Pence P (1982) Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 9:17-23. – reference: Haney M, Ward A, Comer S, Foltin R, Fischman M (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385-394. – reference: Haney M, Hart C, Vosburg S, Nasser J, Bennett A, Zubaran C, Foltin R (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158-170. – reference: Lile J, Kelly T, Hays L (2010) Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta-9-Tetrahydrocannabinol. Clin Neuropharmacol 33:235-242. – reference: Haney M, Hart C, Vosburg S, Comer S, Reed S, Foltin R (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197:157-168. – reference: McGilveray I (2005) Pharmacokinetics of cannabinoids. Pain Res Manag 10 (Suppl. A): 15A-22A. – reference: Lemberger L, Rowe H (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18:720-726. – reference: Parrott AC, Garnham NJ, Wesnes K, Pincock C (1996) Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Hum Psychopharmacol 11:391-400. – reference: APA (1994) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association. – reference: Threlkeld M, Parran T, Adelman C, Grey S, Yu J (2006) Tramadol versus buprenorpine for the management of acute heroin withdrawal: a retrospective matched cohort control study. Am J Addict 15:186-191. – reference: Haney M, Rabkin J, Gunderson E, Foltin R (2005) Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 181:170-178. – reference: Ben Amar M (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105:1-25. – reference: Hart C, van Gorp W, Haney M, Foltin R, Fischman M (2001) Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25:757-765. – reference: Kadden RM, Litt MD, Kabela-Cormier E, Petry NM (2007) Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 32:1220-1236. – reference: Wesnes K, Annas P, Edgar C, Deeprose C, Karlsten R, Philipp A, Kalliomaki J, Segerdahl M (2010) Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol 24:1659-1669. – reference: Fraser A, Meatherall R (1989) Lack of interference by Nabilone in the EMIT® d.a.u cannabinoid assay, Abbott TDx® cannabinoid assay, and a sensitive TLC assay for delta-9-THC-carboxylic acid. J Anal Toxicol 13:240. – reference: Folstein MF, Luria R (1973) Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3:479-486. – reference: Vandrey RG, Budney AJ, Hughes JR, Liguori A (2008) A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 92:48-54. – reference: Levin F, Mariani J, Brooks D, Pavlicova M, Cheng W, Nunes E (2011) Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116:142-150. – reference: Budney AJ, Moore BA, Rocha HL, Higgins ST (2006) Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 74:307-316. – reference: United Nations Office on Drugs and Crime (2007) 2007 World Drug Report. Vienna, Austria: UNODC. – reference: Grassi MC, Enea D, Ferketich AK, Lu B, Pasquariello S, Nencini P (2011) Effectiveness of varenicline for smoking cessation: a 1-year follow-up study. J Subst Abuse Treat 41:64-70. – reference: Zobel I, Kech S, van Calker D, Dykierek P, Berger M, Schneibel R, Schramm E (2011) Long-term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patients. Acta Psychiatr Scand 123:276-282. – reference: Budney A, Roffman R, Stephens R, Walker D (2007a) Marijuana dependence and its treatment. Addict Sci Clin Pract 4:4-16. – reference: Lile J, Kelly T, Hays L (2011) Separate and combined effects of the cannabinoid agonists nabilone and delta9-THC in humans discriminating delta9-THC. Drug Alcohol Depend 116:86-92. – reference: Haney M (2008) Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14:9-21. – volume: 32 start-page: 1391 year: 2007 end-page: 1403 article-title: Opioid antagonism of cannabinoid effects: differences between marijuana smokers and non‐marijuana smokers publication-title: Neuropsychopharmacology – volume: 106 start-page: 824 year: 2011 end-page: 832 article-title: Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo‐controlled trial publication-title: Addiction – volume: 15 start-page: 186 year: 2006 end-page: 191 article-title: Tramadol versus buprenorpine for the management of acute heroin withdrawal: a retrospective matched cohort control study publication-title: Am J Addict – volume: 116 start-page: 142 year: 2011 end-page: 150 article-title: Dronabinol for the treatment of cannabis dependence: a randomized, double‐blind, placebo‐controlled trial publication-title: Drug Alcohol Depend – volume: 33 start-page: 235 year: 2010 end-page: 242 article-title: Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta‐9‐Tetrahydrocannabinol publication-title: Clin Neuropharmacol – volume: 32 start-page: 1220 year: 2007 end-page: 1236 article-title: Abstinence rates following behavioral treatments for marijuana dependence publication-title: Addict Behav – volume: 181 start-page: 170 year: 2005 end-page: 178 article-title: Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood publication-title: Psychopharmacology – volume: 141 start-page: 395 year: 1999b end-page: 404 article-title: Abstinence symptoms following smoked marijuana in humans publication-title: Psychopharmacology – volume: 25 start-page: 757 year: 2001 end-page: 765 article-title: Effects of acute smoked marijuana on complex cognitive performance publication-title: Neuropsychopharmacology – volume: 18 start-page: 720 year: 1975 end-page: 726 article-title: Clinical pharmacology of nabilone, a cannabinol derivative publication-title: Clin Pharmacol Ther – volume: 212 start-page: 675 year: 2010 end-page: 686 article-title: Efficacy and tolerability of high‐dose dronabinol maintenance in HIV‐positive marijuana smokers: a controlled laboratory study publication-title: Psychopharmacology – year: 2007 – volume: 83 start-page: 351 year: 1984 end-page: 356 article-title: Reinforcing effects of oral delta‐9 tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use publication-title: Psychopharmacology – volume: 72 start-page: 455 year: 2004 end-page: 466 article-title: Brief treatments for cannabis dependence: findings from a randomized multisite trial publication-title: J Consult Clin Psychol – year: 2000 – volume: 123 start-page: 276 year: 2011 end-page: 282 article-title: Long‐term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patients publication-title: Acta Psychiatr Scand – volume: 92 start-page: 48 year: 2008 end-page: 54 article-title: A within‐subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances publication-title: Drug Alcohol Depend – volume: 141 start-page: 385 year: 1999a end-page: 394 article-title: Abstinence symptoms following oral THC administration to humans publication-title: Psychopharmacology – volume: 105 start-page: 494 year: 2010 end-page: 503 article-title: The abuse potential of the synthetic cannabinoid nabilone publication-title: Addiction – volume: 3 start-page: 479 year: 1973 end-page: 486 article-title: Reliability, validity, and clinical application of the Visual Analogue Mood Scale publication-title: Psychol Med – volume: 41 start-page: 64 year: 2011 end-page: 70 article-title: Effectiveness of varenicline for smoking cessation: a 1‐year follow‐up study publication-title: J Subst Abuse Treat – volume: 29 start-page: 158 year: 2004 end-page: 170 article-title: Marijuana withdrawal in humans: effects of oral THC or divalproex publication-title: Neuropsychopharmacology – volume: 24 start-page: 1659 year: 2010 end-page: 1669 article-title: Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers publication-title: J Psychopharmacol – year: 1994 – volume: 74 start-page: 307 year: 2006 end-page: 316 article-title: Clinical trial of abstinence‐based vouchers and cognitive‐behavioral therapy for cannabis dependence publication-title: J Consult Clin Psychol – volume: 46 start-page: 53 year: 1997 end-page: 67 article-title: Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States publication-title: Drug Alcohol Depend – year: 2010 – volume: 42 start-page: 34S year: 2002 end-page: 40S article-title: Effects of smoked marijuana in healthy and HIV + marijuana smokers publication-title: J Clin Psychopharmacol – volume: 13 start-page: 240 year: 1989 article-title: Lack of interference by Nabilone in the EMIT® d.a.u cannabinoid assay, Abbott TDx® cannabinoid assay, and a sensitive TLC assay for delta‐9‐THC‐carboxylic acid publication-title: J Anal Toxicol – volume: 165 start-page: 55 year: 2011 end-page: 60 article-title: Developmental trajectories of marijuana use from adolescence to adulthood publication-title: Arch Pediatr Adolesc Med – volume: 11 start-page: 391 year: 1996 end-page: 400 article-title: Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours publication-title: Hum Psychopharmacol – volume: 116 start-page: 86 year: 2011 end-page: 92 article-title: Separate and combined effects of the cannabinoid agonists nabilone and delta9‐THC in humans discriminating delta9‐THC publication-title: Drug Alcohol Depend – volume: 32 start-page: 503 year: 2006 end-page: 517 article-title: Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? publication-title: Am J Drug Alcohol Abuse – volume: 105 start-page: 1 year: 2006 end-page: 25 article-title: Cannabinoids in medicine: a review of their therapeutic potential publication-title: J Ethnopharmacol – volume: 96 start-page: 333 year: 2010 end-page: 341 article-title: Neurophysiological and cognitive effects of smoked marijuana in frequent users publication-title: Pharmacol Biochem Behav – volume: 86 start-page: 22 year: 2007b end-page: 29 article-title: Oral delta‐9‐tetrahydrocannabinol suppresses cannabis withdrawal symptoms publication-title: Drug Alcohol Depend – volume: 14 start-page: 9 year: 2008 end-page: 21 article-title: Self‐administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls publication-title: Addict Biol – volume: 181 start-page: 237 year: 2005 end-page: 243 article-title: Reinforcing effects of oral Delta‐9‐THC in male marijuana smokers in a laboratory choice procedure publication-title: Psychopharmacology – volume: 4 start-page: 4 year: 2007a end-page: 16 article-title: Marijuana dependence and its treatment publication-title: Addict Sci Clin Pract – volume: 10 start-page: 15A year: 2005 end-page: 22A article-title: Pharmacokinetics of cannabinoids publication-title: Pain Res Manag – year: 1991 – volume: 197 start-page: 157 year: 2008 end-page: 168 article-title: Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse publication-title: Psychopharmacology – volume: 9 start-page: 17 year: 1982 end-page: 23 article-title: Pharmacokinetics, metabolism and drug‐abuse potential of nabilone publication-title: Cancer Treat Rev |
| SSID | ssj0012753 |
| Score | 2.3002427 |
| Snippet | ABSTRACT
Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies,... Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the... |
| SourceID | pubmedcentral proquest pubmed wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 872 |
| SubjectTerms | Addiction Adult Affect - drug effects Agonist treatment Analysis of Variance Biological Availability Blood Pressure - drug effects Cannabinoid Receptor Agonists - pharmacokinetics Cannabinoid Receptor Agonists - pharmacology Cannabinoid Receptor Agonists - therapeutic use dose-effect profile Dose-Response Relationship, Drug Double-Blind Method dronabinol Dronabinol - analogs & derivatives Dronabinol - pharmacokinetics Dronabinol - pharmacology Dronabinol - therapeutic use Female Heart Rate - drug effects Humans Male Marijuana Abuse - drug therapy marijuana dependence Middle Aged nabilone Placebos Psychomotor Performance - drug effects Secondary Prevention Substance Withdrawal Syndrome - prevention & control Time Factors Young Adult |
| Title | Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers |
| URI | https://api.istex.fr/ark:/67375/WNG-7Q8L4NB3-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1369-1600.2011.00427.x https://www.ncbi.nlm.nih.gov/pubmed/22260337 https://www.proquest.com/docview/1463073385 https://www.proquest.com/docview/1426750064 https://www.proquest.com/docview/1492619328 https://pubmed.ncbi.nlm.nih.gov/PMC3335956 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdge-EF8U2gICOhvYygJk7i5LFlKxUqRaBWq3ixnMQRXbdk6gea-Ou5ix2n1app8BKlju0mvp99d_Z9EPKe-3lUcOa7rJvloKAkiZtmMndTXiheAM-Lavexr-NoOA2-zMJZa9Zce5es04_Zn71-Jf9DVSgDuqKX7D9Q1nYKBXAP9IUrUBiud6IxzPpzvWDhSLWWQLWv2q6haV6tlKtMqGKdp7u24cAAu1Wpm-TLCn-XFcbhOL4ELfp8I0t5vLqsFsZQ3gaszfO5TjJuojhZtR6YYb3Xjvs46DhjDzmq6krD4-f8t2wNjYfS2Js1KXe39yEwJ0TS7EPopZNFietFXX3KovaU3Vhv2xNtw3n92xf1pjcTeRXThDTGnttxtMffxGA6GonJ6Wxynxz6nOMB_mGvf9If2BMmX0cotX3uWnnt_SfQX3DqXe9TRm7a1G7rOrWwMnlEHhotg_Y0ZB6Te6p8QjraFZueqYsCBpoe0aagWi6ekosWTR-oxRIFYNBdLNEtLFGDJVoVtMFS3aTFEp2X1GKJGiw9I9PB6eTT0DW5ONx54AEf8goUxRn3fJnFEtVYiaEZZeCnIKEqzsNEgqSDEr1ieVp0U48rL_N5EKKVYMaek4MSXuEloXGhEgWyGcjqRcB5moaoxMcSmI2nQhU55KgeZnGl460IuVyg-SEPxdn4s-Df41Ew7jPxwyGdhg7CzMoVqrLItlgcOuSdfQxrJh6EAaKrDdbxQU9Gafy2OgluLjA_dsgLTVr7QiBTR13GuEP4DtFtBYzZvvuknP-qY7czhp7w8I1hDQ_bYksXB-wJxJ5A7Ikae-Ja9E76cPPqDt_0mjxo52eHHKyXG_UGJOd1-tZMgr87bMIz |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subjective%2C+cognitive+and+cardiovascular+dose-effect+profile+of+nabilone+and+dronabinol+in+marijuana+smokers&rft.jtitle=Addiction+biology&rft.au=Bedi%2C+Gillinder&rft.au=Cooper%2C+Ziva+D&rft.au=Haney%2C+Margaret&rft.date=2013-09-01&rft.issn=1369-1600&rft.eissn=1369-1600&rft.volume=18&rft.issue=5&rft.spage=872&rft_id=info:doi/10.1111%2Fj.1369-1600.2011.00427.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1355-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1355-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1355-6215&client=summon |